Latest Pharmaceuticals News

Page 12 of 25
Bioxyne Limited reports a record-breaking Q4 FY25 with revenue soaring 204% year-on-year and a strategic entry into the German market through a €3.2 million manufacturing agreement.
Victor Sage
Victor Sage
24 July 2025
Island Pharmaceuticals reported promising Phase 2a/b trial results for its dengue drug ISLA-101 and secured a strategic acquisition of the broad-spectrum antiviral Galidesivir, bolstering its pipeline and balance sheet.
Ada Torres
Ada Torres
24 July 2025
Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.
Ada Torres
Ada Torres
23 July 2025
Firebrick Pharma has published positive Phase 3 clinical trial results for its Nasodine nasal spray, showing efficacy against the common cold, while reporting encouraging sales growth in Singapore and the US. However, a recent capital raise fell well short of targets, casting uncertainty over its expansion plans.
Ada Torres
Ada Torres
23 July 2025
Bod Science reports a solid net cash inflow of $858,000 in Q4 FY2025, driven by R&D incentives and Biortica funding, while awaiting shareholder approval to complete a key acquisition.
Ada Torres
Ada Torres
22 July 2025
InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.
Ada Torres
Ada Torres
22 July 2025
EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.
Ada Torres
Ada Torres
21 July 2025
Nyrada has successfully dosed and discharged the final participants in its Phase I trial of Xolatryp, reporting no adverse safety signals and setting the stage for Phase II development.
Ada Torres
Ada Torres
21 July 2025
IDT Australia has signed a memorandum with NASDAQ-listed Gelteq to establish a dedicated gel-based product manufacturing facility, marking a strategic expansion in pharmaceutical delivery technologies.
Victor Sage
Victor Sage
17 July 2025
Nyrada has initiated the last cohort of its Phase I trial for Xolatryp, following a clean safety review of the highest dose tested so far. This step sets the stage for critical data that could shape the drug’s next development phase.
Ada Torres
Ada Torres
14 July 2025
Hydralyte USA has completed its Rights Issue by placing 5 million shortfall shares, raising a total of $608,878 before costs. The move finalizes the company’s recent capital raising efforts under full regulatory compliance.
Ada Torres
Ada Torres
10 July 2025
Island Pharmaceuticals has accelerated its acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals, adding a clinically advanced asset with significant US government backing and a promising regulatory pathway.
Victor Sage
Victor Sage
9 July 2025